Anti‐Cytokine Active Immunotherapy Based on Supramolecular Peptides for Alleviating IL‐1β‐Mediated Inflammation
Advanced Healthcare Materials · 2025-02 · 14 (5)
DOI: 10.1002/adhm.202401444 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, online erschienen am 07.08.2024. Verfasst von Shamitha Shetty und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Engineering, Duke University, Durham, NC, 27705, USA. Hauptthemen laut MEDLINE: Interleukin-1beta, Nanofibers, Peptides, Inflammation. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NIH HHS, North Carolina Biotechnology Center.
Abstract (Originalsprache)
IL‐1β is a principal proinflammatory cytokine underlying multiple local and systemic chronic inflammatory conditions including psoriasis, rheumatoid arthritis, inflammatory bowel disease, and type 2 diabetes. Passive immunotherapies and biologic drugs targeting IL‐1β, while offering significant clinical benefit, nevertheless have limitations such as significant non‐response rates, induction of anti‐drug antibodies, and high costs. Here, an active immunotherapy raising antibody responses against IL‐1β employing self‐assembling peptide nanofibers is described. The nanofibers contain defined quantities of B‐cell epitopes from IL‐1β and exogenous T helper epitopes and employ the Q11 self‐assembling peptide platform. Without adjuvant, the nanofibers raised durable anti‐IL‐1β antibody responses that inhibit IL‐1β activity in vitro and in vivo. In a mouse model of imiquimod‐induced psoriasis, prophylactic immunizations with the nanofibers diminished symptoms of epidermal thickening. This therapeutic effect is associated with biasing the immune response toward an anti‐inflammatory IgG1/Th2 phenotype and a lowered expression of proinflammatory genes in the skin. Further, anti‐IL‐1β nanofibers induced therapeutic immunosuppressive CD62L+ Treg cells. This technology represents a potential alternative for passive immunotherapies and other biologics for treating chronic inflammatory conditions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biomedical Engineering, Duke University, Durham, NC, 27705, USA.
ORCID-Profile: Shamitha Shetty, Joel H Collier
Förderung
- NIAID NIH HHS
- NIH HHS
- North Carolina Biotechnology Center
- NIBIB NIH HHS
- National Institutes of Health
Zitieren
APA
Shetty, S., Wu, Y., Lloyd, C. Z., Mehta, N., Liu, Y., Woodruff, M. E., Segura, T., & Collier, J. H. (2025). Anti‐Cytokine Active Immunotherapy Based on Supramolecular Peptides for Alleviating IL‐1β‐Mediated Inflammation. Advanced Healthcare Materials, 14(5). https://doi.org/10.1002/adhm.202401444
Vancouver
Shetty S, Wu Y, Lloyd CZ, Mehta N, Liu Y, Woodruff ME, et al. Anti‐Cytokine Active Immunotherapy Based on Supramolecular Peptides for Alleviating IL‐1β‐Mediated Inflammation. Advanced Healthcare Materials. 2025;14(5). doi:10.1002/adhm.202401444
BibTeX
@article{Shetty2025,
author = {Shetty, Shamitha and Wu, Yaoying and Lloyd, Christopher Z and Mehta, Nalini and Liu, Yining and Woodruff, Mia E and Segura, Tatiana and Collier, Joel H},
title = {Anti‐Cytokine Active Immunotherapy Based on Supramolecular Peptides for Alleviating IL‐1β‐Mediated Inflammation},
journal = {Advanced Healthcare Materials},
year = {2025},
volume = {14},
number = {5},
doi = {10.1002/adhm.202401444}
}
EUVIMED